TY - JOUR
T1 - A novel minor histocompatibility antigen recognized by HLA-A31 restricted cytotoxic T lymphocytes generated from HLA-identical bone marrow donor lymphocytes
AU - Yazaki, M.
AU - Takahashi, T.
AU - Andho, M.
AU - Akatsuka, Y.
AU - Ito, T.
AU - Miyake, Y.
AU - Ito, Y.
AU - Nakamura, S.
AU - Wada, Y.
N1 - Funding Information:
We thank Dr Elis Goulmy for sending the protocol regarding the generation of mHAg-specific CTL. We also thank Dr Yoshihiro Komada for providing the moAbs against CD3 and CD4 and Dr Hirokazu Komatsu, Dr Koji Kato, Dr Keizo Horibe, Dr Mitsune Tanimoto, Dr Shigeru Tsuchiya and Dr Shinichiro Nishimura for kindly giving HLA-A31-positive leukemic cells. We thank Mrs Etsuko Maruya for analysis of polymorphism of adhesion molecules in EBV-LCLs and Mr Dee Lynn Johnson for his advice on this manuscript. This work was supported in part by a Grant-in-Aid for Scientific Research on Priority Areas, from the Ministry of Education, Science, Sports and Culture, Japan, and a Bristol-Myers-Squibb Biomedical Research Grant.
PY - 1999
Y1 - 1999
N2 - Bulk cytotoxic T lymphocytes (CTL) were generated by in vitro stimulation of BMT donor lymphocytes with Philadelphia chromosome (Ph)-positive leukemic cells from an HLA-identical sibling patient. CTL were cytotoxic against the patient's leukemic cells as well as the EBV-lymphoblastoid cell line (EBV-LCL) generated from the patient's cells, suggesting that they recognize a minor histocompatibility antigen (mHAg). Subsequently, several CTL lines were established by a limiting dilution method and analyzed. One of these CTL lines, 16C12 CTL which used a single TCRβV3S1 for CD8 cells, lysed HLA-A31-positive leukemic cells and EBV-LCL, but not fibroblasts. The cytotoxicity against the patient's leukemic cells and EBV-LCL was blocked by anti-HLA-A31 moAb, anti-HLA-class I moAb, and anti-CD8 moAb, suggesting that this mHAg was presented with HLA-A31. The antigen recognized by 16C12 CTL seemed to be a novel mHAg, since HLA-A31 restricted antigen has not been reported to date and 16C12 CTL showed no cytotoxicity against EBV-LCL which probably express known mHAgs. CTL detecting this mHAg may play an important role in the GVL effect in HLA-A31-positive BMT patients.
AB - Bulk cytotoxic T lymphocytes (CTL) were generated by in vitro stimulation of BMT donor lymphocytes with Philadelphia chromosome (Ph)-positive leukemic cells from an HLA-identical sibling patient. CTL were cytotoxic against the patient's leukemic cells as well as the EBV-lymphoblastoid cell line (EBV-LCL) generated from the patient's cells, suggesting that they recognize a minor histocompatibility antigen (mHAg). Subsequently, several CTL lines were established by a limiting dilution method and analyzed. One of these CTL lines, 16C12 CTL which used a single TCRβV3S1 for CD8 cells, lysed HLA-A31-positive leukemic cells and EBV-LCL, but not fibroblasts. The cytotoxicity against the patient's leukemic cells and EBV-LCL was blocked by anti-HLA-A31 moAb, anti-HLA-class I moAb, and anti-CD8 moAb, suggesting that this mHAg was presented with HLA-A31. The antigen recognized by 16C12 CTL seemed to be a novel mHAg, since HLA-A31 restricted antigen has not been reported to date and 16C12 CTL showed no cytotoxicity against EBV-LCL which probably express known mHAgs. CTL detecting this mHAg may play an important role in the GVL effect in HLA-A31-positive BMT patients.
UR - http://www.scopus.com/inward/record.url?scp=0032771691&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032771691&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1701856
DO - 10.1038/sj.bmt.1701856
M3 - Article
C2 - 10455340
AN - SCOPUS:0032771691
SN - 0268-3369
VL - 24
SP - 129
EP - 137
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 2
ER -